The in vitro effecteffect of new combinations of carbapenem-ßlactamase inhibitors for MycobacteriumabscessusMycobacterium abscessus

Article Immunology

A Rough Colony Morphology of Mycobacterium abscessus Is Associated With Cavitary Pulmonary Disease and Poor Clinical Outcome

Wilhelm Hedin et al.

Summary: The morphology of MABC is associated with disease and treatment outcome, with smooth isolates having more favorable outcomes compared to rough isolates.

JOURNAL OF INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Infectious Diseases

Towards clinical breakpoints for non-tuberculous mycobacteria-Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution

Gabrielle Froberg et al.

Summary: The study evaluated the minimum inhibitory concentration (MIC) distributions of non-tuberculous mycobacteria (NTM) to establish antimicrobial susceptibility testing (AST) breakpoints. MIC distributions for drugs against Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) were collected from 12 laboratories. Epidemiological cut-off values (ECOFFs) and tentative ECOFFs (TECOFFs) were determined, highlighting the need for further method refinement in establishing clinical breakpoints for NTM.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

添加到收藏夹

Article Microbiology

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection

Dereje A. Negatu et al.

Summary: The combination of tebipenem and avibactam, both belonging to the beta-lactam class, exhibits strong bactericidal activity against Mycobacterium abscessus in vitro. In a mouse model of M. abscessus lung infection, the combination of their respective oral prodrugs, tebipenem-pivoxil and avibactam ARX-1796, showed efficacy. These findings suggest that tebipenem-avibactam is a promising oral drug candidate for the treatment of M. abscessus pulmonary disease and could guide the design of clinical trials.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

添加到收藏夹

Article Medicine, General & Internal

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection

Paul B. Eckburg et al.

Summary: This study demonstrated the noninferiority of orally administered tebipenem pivoxil hydrobromide compared to intravenous ertapenem in the treatment of complicated urinary tract infection and acute pyelonephritis, with similar safety profiles.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Microbiology

Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease

Dereje A. Negatu et al.

Summary: This study screened the bioactive forms of oral beta-lactams against Mycobacterium abscessus in vitro, both with and without the bioactive form of the oral beta-lactamase inhibitor avibactam ARX1796. The results showed that sulopenem was equally effective without avibactam, while tebipenem, cefuroxime, and amoxicillin required avibactam for optimal activity. Furthermore, systematic pairing of the four beta-lactams revealed strong synergistic bactericidal effects when combined with amoxicillin in the presence of avibactam. These findings highlight the potential clinical value of these all-oral beta-lactam combinations.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

In vitro effects of diazabicyclooctane ?-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex

Kana Misawa et al.

Summary: This study investigated the effects of the combination of β-lactams and DBO β-lactamase inhibitors on MABC, and found that relebactam and nacubactam improved the efficacy of β-lactams against all MABC subspecies.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

添加到收藏夹

Article Microbiology

Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease

Keiji Fujiwara et al.

Summary: The retrospective analysis of MIC results from isolates of rapidly growing mycobacteria from 92 patients with nontuberculous mycobacterial pulmonary disease revealed that Mma were significantly more susceptible to clarithromycin and azithromycin than Mab. Most isolates were susceptible to amikacin and linezolid, while the susceptibility to imipenem was lower.

MICROBIOLOGY SPECTRUM (2021)

添加到收藏夹

Article Microbiology

β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates

Elizabeth Story-Roller et al.

Summary: Mycobacteroides abscessus is a difficult-to-treat environmental pathogen that can cause chronic pulmonary disease in patients with underlying structural lung conditions. Current treatment options are often ineffective and associated with significant toxicities, with the pathogen naturally resistant to many antibiotics.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Infectious Diseases